LumiHeal is an early-stage commercial asset (CE mark) with applications in wound care, specifically targeting chronic and complex wounds by providing fluorescence at a cellular level to impact the three (3) critical phases of wound healing: inflammation, proliferation and remodeling. LumiHeal is an active wound care solution that delivers high response rates and ignites the onset of wound regression, while providing an excellent safety profile.
Klox and LEO Pharma, a global leader in dermatology, created FBD, a specialized company to commercialize Kleresca. The Kleresca line of products are commercialized and designed to target specific dermatological needs, namely moderate to severe acne vulgaris and skin rejuvenation. Kleresca stimulates the skin’s own repair mechanisms through fluorescence, helping to reduce inflammation, increase the build-up of collagen and normalize cellular activity.
The Phovia line of products are clinical assets with applications in canine pyoderma, wounds in dogs, cats and horses as well canine chronic otitis externa. This device improves the clinical outcome for animal patients by accelerating time to clinical remission and has the potential to reduce the duration and/or reliance on antibiotics in severe wound cases and in deep pyoderma.
PERIO-1 is a late-stage clinical asset (CE mark) with applications as an adjunct to scaling and root planing (SRP), for the treatment of moderate to severe chronic periodontitis. The application facilitates periodontal pocket debridement, decreases localized pain and inflammation, emulsifies bacterial biofilm enabling the easy removal of bacteria and accelerates periodontal pocket and gum reattachment.